Antibiotic resistance threats in the United States, 2019

[1]  Michael Bell,et al.  Vital Signs: Carbapenem-Resistant Enterobacteriaceae , 2013, MMWR. Morbidity and mortality weekly report.

[2]  S. Magill,et al.  Changes in incidence and antifungal drug resistance in candidemia: results from population-based laboratory surveillance in Atlanta and Baltimore, 2008-2011. , 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[3]  T. Lieu,et al.  Healthcare utilization and cost of pneumococcal disease in the United States. , 2011, Vaccine.

[4]  M. Widdowson,et al.  Foodborne Illness Acquired in the United States—Major Pathogens , 2011, Emerging infectious diseases.

[5]  J. Crump,et al.  Global trends in typhoid and paratyphoid Fever. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[6]  Bala Hota,et al.  Hospital and societal costs of antimicrobial-resistant infections in a Chicago teaching hospital: implications for antibiotic stewardship. , 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[7]  E. Mintz,et al.  High Prevalence of Antimicrobial Resistance among Shigella Isolates in the United States Tested by the National Antimicrobial Resistance Monitoring System from 1999 to 2002 , 2006, Antimicrobial Agents and Chemotherapy.

[8]  J. Wells,et al.  Antimicrobial resistance of Shigella isolates in the USA: the importance of international travelers. , 1990, The Journal of infectious diseases.

[9]  M. Ferraro.  Performance standards for antimicrobial susceptibility testing , 2001 .